Risk Factors of Breakthrough Urinary Tract Infection in Children with Primary Vesicoureteral Reflux
Abstract
Objective: Vesicoureteral reflux (VUR) is a significant risk factor for urinary tract infections (UTI) in children, potentially leading to renal damage. Antibiotic prophylaxis is essential for the pediatric patients with VUR aiming to reduce the chance of UTI. However, breakthroughs UTI can occurred despite adequate prophylactic antibiotics. We aimed to identify the factors contributing to breakthrough UTIs in the patients with VUR.
Material and Methods: This retrospective study analyzed medical records from 238 children with primary VUR from 2000-2019. This study included children aged less than 10 years old at the time of VUR diagnosis and excluded those with secondary VUR, incomplete medical records, or lost to follow-up. Univariate and multivariate analyses were utilized to determine the predictors of breakthrough UTIs.
Results: This study comprised 238 children diagnosed with VUR, including 133 males and 105 females; 86 patients experienced a breakthrough infection. Multivariate analysis revealed that each additional UTI before prophylactic antibiotics significantly increased the likelihood of breakthrough infections (OR 1.62; 95% CI 1.10-2.37; p-value=0.013). Upper pole renal scarring and generalized abnormal renal scans were also significant risk factors with OR 5.57; 95% CI (2.16-14.40); p-value<0.001 and OR 5.19; 95% CI (1.36-19.75); p-value=0.016, respectively. Bowel bladder symptoms emerged as a substantial risk factor (OR 30.16; 95% CI 1.43-633.86; p-value=0.028), whereas the use of cephalexin appeared protective (OR 0.22; 95% CI 0.05-0.94; p-value=0.042).
Conclusion: The number of UTIs before prophylaxis antibiotics, abnormal renal scan at the upper pole and generalized kidney and bowel bladder symptoms were independent risk factors for breakthrough infections. Moreover, the study showed that the use of cephalexin was a statistically significant protective factor against breakthrough UTI.
Keywords
Full Text:
PDFReferences
Mattoo TK, Mohammad D. Primary vesicoureteral reflux and renal scarring. Pediatr Clin North Am 2022;69:1115-29.
Senekjian HO, Suki WN. Vesicoureteral reflux and reflux nephropathy. Am J Nephrol 1982;2:245-50.
Davis TD, Rushton HG. Managing vesicoureteral reflux in the pediatric patient: a spectrum of treatment options for a spectrum of disease. Current treatment options in pediatrics. 2016;2:23-34.
Lebowitz RL, Olbing H, Parkkulainen KV, Smellie JM, Tamminen-Möbius TE. International system of radiographic grading of vesicoureteric reflux. International Reflux Study in Children. Pediatr Radiol 1985;15:105-9.
Mingin GC, Nguyen HT, Baskin LS, Harlan S. Abnormal dimercapto-succinic acid scans predict an increased risk of breakthrough infection in children with vesicoureteral reflux. J Urol 2004;172:1075-7.
Shiraishi K, Yoshino K, Watanabe M, Matsuyama H, Tanikaze S. Risk factors for breakthrough infection in children with primary vesicoureteral reflux. J Urol 2010;183:1527-31.
Nakamura M, Moriya K, Mitsui T, Tanaka H, Nonomura K. Abnormal dimercapto-succinic acid scan is a predictive factor of breakthrough urinary tract infection in children with primary vesicoureteral reflux. J Urol 2009;182(Suppl4):1694-7.
Jang HC, Park YJ, Park JS. Predicting factors of breakthrough infection in children with primary vesicoureteral reflux. Yonsei Med J 2012;53:748-52.
Soylu A, Demir BK, Türkmen M, Bekem O, Saygi M, Cakmakçi H, et al. Predictors of renal scar in children with urinary infection and vesicoureteral reflux. Pediatr Nephrol 2008;23:2227-32.
Santos JD, Lopes RI, Koyle MA. Bladder and bowel dysfunction in children: An update on the diagnosis and treatment of a common, but underdiagnosed pediatric problem. Can Urol Assoc J 2017;11(1-2Suppl1):S64-72.
Su D, Zhuo Z, Zhang J, Zhan Z, Huang H. Risk factors for new renal scarring in children with vesicoureteral reflux receiving continuous antibiotic prophylaxis. Sci Rep 2024;14:1784.
Penaranda C, Chumbler NM, Hung DT. Dual transcriptional analysis reveals adaptation of host and pathogen to intracellular survival of Pseudomonas aeruginosa associated with urinary tract infection. PLoS Pathog 2021;17:e1009534.
Lashkar MO, Nahata MC. Antimicrobial pharmacotherapy management of urinary tract infections in pediatric patients. J Pharm Technol 2018;34:62-81.
Wu SY, Jiang YH, Jhang JF, Hsu YH, Ho HC, Kuo HC. Inflammation and barrier function deficits in the bladder urothelium of patients with chronic spinal cord injury and recurrent urinary tract infections. Biomedicines 2022;10.
Cendron M. Antibiotic prophylaxis in the management of vesicoureteral reflux. Adv Urol 2008;2008:825475.
Carpenter MA, Hoberman A, Mattoo TK, Mathews R, Keren R, Chesney RW, et al. The RIVUR trial: profile and baseline clinical associations of children with vesicoureteral reflux. Pediatrics 2013;132:e34-45.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.